Tarsus Pharmaceuticals Inc’s filing revealed that its President/CEO and Board Chair Azamian Bobak R. unloaded Company’s shares for reported $0.32 million on Mar 18 ’24. In the deal valued at $30.60 per share,10,415 shares were sold. As a result of this transaction, Azamian Bobak R. now holds 26,456 shares worth roughly $0.92 million.
Then, Neervannan Seshadri sold 4,879 shares, generating $149,297 in total proceeds. Upon selling the shares at $30.60, the Chief Operating Officer now owns 64,767 shares.
Before that, Mottiwala Aziz sold 4,766 shares. Tarsus Pharmaceuticals Inc shares valued at $145,840 were divested by the Chief Commercial Officer at a price of $30.60 per share. As a result of the transaction, Mottiwala Aziz now holds 54,075 shares, worth roughly $1.88 million.
Goldman initiated its Tarsus Pharmaceuticals Inc [TARS] rating to a Neutral in a research note published on November 20, 2023; the price target was $19. A number of analysts have revised their coverage, including William Blair’s analysts, who began to cover the stock in mid July with a ‘”an Outperform”‘ rating. Guggenheim began covering TARS with “Buy” recommendation on May 18, 2023. Barclays started covering the stock on August 01, 2022. It rated TARS as “an Overweight”.
Price Performance Review of TARS
On Friday, Tarsus Pharmaceuticals Inc [NASDAQ:TARS] saw its stock fall -0.57% to $34.74. Over the last five days, the stock has lost -4.43%. Tarsus Pharmaceuticals Inc shares have risen nearly 71.56% since the year began. Nevertheless, the stocks have risen 178.37% over the past one year. While a 52-week high of $40.40 was reached on 02/28/24, a 52-week low of $11.33 was recorded on 01/05/24. SMA at 50 days reached $32.31, while 200 days put it at $21.40. A total of 0.74 million shares were traded, compared to the trading of 0.5 million shares in the previous session.
Levels Of Support And Resistance For TARS Stock
The 24-hour chart illustrates a support level at 34.23, which if violated will result in even more drops to 33.71. On the upside, there is a resistance level at 35.36. A further resistance level may holdings at 35.97. The Relative Strength Index (RSI) on the 14-day chart is 55.12, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.98, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 34.30%. Stochastics %K at 72.52% indicates the stock is a holding.
How much short interest is there in Tarsus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Tarsus Pharmaceuticals Inc stocks on Mar 15, 2024, growing by 1.54 million shares to a total of 7.2 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 5.66 million shares. There was a rise of 21.39%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 20.10% of the overall stock float, the days-to-cover ratio (short ratio) rose to 7.37.
The most recent change occurred on December 21, 2021 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $40 price target.
